JRCT ID: jRCT1050210166
Registered date:02/02/2022
Expression of metabolism-related genes in peripheral blood mononuclear cells in patients with dementia
Basic Information
Recruitment status | Complete |
---|---|
Health condition(s) or Problem(s) studied | dementia |
Date of first enrollment | 02/02/2022 |
Target sample size | 20 |
Countries of recruitment | |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Expression of metabolism-related genes in peripheral blood mononuclear cells |
---|---|
Secondary Outcome | 1) Expression of metabolism-related genes in whole peripheral blood 2) MMSE (cognitive Function) Examination and Frailty Interview 3) Complete blood count and peripheral blood image (white blood cell composition) 4) Blood glucose level and HbA1c (sugar, energy metabolism) |
Key inclusion & exclusion criteria
Age minimum | >= 65age old |
---|---|
Age maximum | Not applicable |
Gender | Male |
Include criteria | 1)disease: Elderly healthy people and dementia patients Dementia patients must be diagnosed with probable Alzheimer's disease according to the NIA-AA Alzheimer's disease diagnostic criteria. In the MMSE test, dementia patients should have a score of 23 or less, and the healthy group should have a score of 28 or more. 2)others: For patients with dementia, written consent must be obtained from a substitute other than the person himself (Do not exclude the acquisition of consent from the dementia patient). |
Exclude criteria | 1)Diabetes 2)During cancer disease treatment, less than 5 years after the end of cancer treatment 3)Thyroid disease 4)Infectious diseases (AIDS, hepatitis B, hepatitis C) 5)Fever at the time of blood collection 6)Chronic subdural hematoma 7)Normal pressure hydrocephalus 8)During hemodialysis (or doctors say the need for hemodialysis soon future) 9)COPD 10)During home oxygen therapy 11)Smoking within the last 12 months 12)Taking drugs that have a clear effect on the immune system, such as anti-cancer drugs, steroids, and anti-rheumatic drugs 13)Patients with serious complications, or those who have a history of these and are judged by the investigator and the investigator to be ineligible for this study 14)Others who are judged by the principal investigator and the investigator to be ineligible for this study |
Related Information
Primary Sponsor | Taguchi Akihiko |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Kaneka Corporation |
Secondary ID(s) |
Contact
Public contact | |
Name | Orie Saino |
Address | Institute of Biomedical Research and Innovation 5F, 2-2, Minatojima-Minamimachi, Chuo-ku, Kobe city Hyogo Japan 650-0047 |
Telephone | +81-78-304-5772 |
saino.orie@fbri.org | |
Affiliation | Foundation for Biomedical Research and Innovation at Kobe |
Scientific contact | |
Name | Akihiko Taguchi |
Address | Institute of Biomedical Research and Innovation 5F, 2-2, Minatojima-Minamimachi, Chuo-ku, Kobe city Hyogo Japan 650-0047 |
Telephone | +81-78-304-5772 |
taguchi@fbri.org | |
Affiliation | Foundation for Biomedical Research and Innovation at Kobe |